Breaking News
Get 55% Off 0
🎈 Up Big Today: Find today's biggest gainers with our free screener
Try Stock Screener
Close

Hansa Biopharma AB (HNSAs)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
38.37 0.00    0.00%
28/10 - Closed. Currency in SEK
Type:  Equity
Market:  Euro Zone
ISIN:  SE0002148817 
  • Volume: 0
  • Bid/Ask: 41.66 / 46.84
  • Day's Range: 38.37 - 38.37
Hansa Biopharma 38.37 0.00 0.00%

ST:HNSAs Financials

 
Explore the ST:HNSA financials. Find the Hansa Biopharma financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key financial reports, including the Hansa Biopharma annual report, the income statement, balance sheet, and cash flow statement. Gain deeper insights with financial ratios that assess the company's performance and stability. Users can customize their view by selecting data from four periods of either annual or quarterly information, making it easy to track the financial performance of Hansa Biopharma over time.

Hansa Biopharma AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported sales was SEK 48.66 million compared to SEK 22.84 million a year ago. Net loss was SEK 103.8 million compared to SEK 250.66 million a year ago. Basic loss per share from continuing operations was SEK 1.53 compared to SEK 4.78 a year ago. Diluted loss per share from continuing operations was SEK 1.53 compared to SEK 4.78 a year ago. For the nine months, sales was SEK 138.98 million compared to SEK 83.68 million a year ago. Net loss was SEK 530.32 million compared to SEK 707.26 million a year ago. Basic loss per share from continuing operations was SEK 8.67 compared to SEK 13.49 a year ago. Diluted loss per share from continuing operations was SEK 8.67 compared to SEK 13.49 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

HNSAs Income Statement

Gross margin TTM 53.43%
Operating margin TTM -330.77%
Net Profit margin TTM -345.73%
Return on Investment TTM 0%
 Total Revenue  Net Income
Period Ending: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023
Total Revenue 48.66 34.33 55.98 50.41
Gross Profit 37.28 -6.19 37.82 32.28
Operating Income -116.93 -187.38 -159.39 -175.54
Net Income -103.8 -207.94 -218.58 -124.46

HNSAs Balance Sheet

Quick Ratio MRQ 2.3
Current Ratio MRQ 2.45
LT Debt to Equity MRQ 0%
Total Debt to Equity MRQ -299.78%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023
Total Assets 940.68 1029.38 830.55 1018.04
Total Liabilities 1260.63 1248.17 1204.76 1185.92
Total Equity -319.96 -218.79 -374.21 -167.88

HNSAs Cash Flow Statement

Cash Flow/Share TTM -10.32
Revenue/Share TTM 2.79
Operating Cash Flow  -48.92%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -148.8 -189.14 -189.14 -172.94
Cash From Investing Activities -0.116 0.405
Cash From Financing Activities -1.89 352.43 -1.86 -2.2
Net Change in Cash -151.46 163.53 -190.6 -176.12
* In Millions of SEK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

HNSA Comments

Write your thoughts about Hansa Biopharma AB
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
lau panduro
lau panduro Apr 02, 2024 8:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
think it's time to buy ... 2 strong quarter 💪
BumHunters Archer
JohnJenga Sep 06, 2021 6:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1630923594_18712.jpg
Run baby
Peter Hovgaard
Peter Hovgaard Sep 03, 2020 2:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.redeye.se/research/792767/hansa-biopharma-plattformspotential-driver-upp-vardering?utm_source=avanza&utm_medium=RSS
Peter Hovgaard
Peter Hovgaard Aug 26, 2020 2:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://news.cision.com/hansa-biopharma-ab/r/the-eu-commission-grants-conditional-approval-for-idefirix-tm---imlifidase--in-highly-sensitized-kid,c3181977
Peter Hovgaard
Peter Hovgaard Aug 14, 2020 8:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://streamio.com/api/v1/videos/5f3512566f8d8dd4d8000001/public_show
Peter Hovgaard
Peter Hovgaard Aug 13, 2020 5:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://cdn.fbsbx.com/v/t59.2708-21/117831693_1914597025350073_1554897188658194790_n.pdf/Intron-Health-Research-Initiation-Hansa-Biopharma-A-Rare-Gem.pdf?_nc_cat=111&_nc_sid=0cab14&_nc_ohc=7LrlyVybJasAX84jF3U&_nc_ht=cdn.fbsbx.com&oh=3f8350d7915c58e168cbd3df20773c00&oe=5F36E9BE&dl=1
Capstar Go
Capstar Go Jun 25, 2020 5:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Press releases & NewsHansa Biopharma receives positive CHMP opinion for Idefirix[TM] (imlifidase) for kidney transplant in EU
Capstar Go
Capstar Go Jun 25, 2020 4:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
CHMP recommendations approved
Harri Rautiainen
Harri Rautiainen Jun 11, 2018 5:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
152871054577145.jpg
Short-term dipping, in loger run a promising share.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email